Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema
Contact Dermatitis · 2026-07 · 95 (1) · 91-99
DOI: 10.1111/cod.70114 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Contact Dermatitis, online erschienen am 03.03.2026. Verfasst von Andrea Bauer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Allergy Centre, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany. Hauptthemen laut MEDLINE: Dermatologic Agents, Eczema, Hand Dermatoses, Pyrroles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEO Pharma.
Abstract (Originalsprache)
Background
Chronic Hand Eczema (CHE) is a multifactorial, fluctuating inflammatory disease of the hands and wrists that negatively impacts patients' health‐related quality of life (HRQoL).
Objectives
To assess the effects of delgocitinib cream versus cream vehicle on HRQoL.
Methods
DELTA 1 and DELTA 2 were phase 3 trials of identical design in which adults with moderate to severe CHE were randomised (2:1) to double‐blind treatment with delgocitinib cream 20 mg/g or cream vehicle twice daily for 16 weeks. Data were pooled from both trials and changes in EQ‐5D, Dermatology Life Quality Index (DLQI), and Hand Eczema Impact Scale (HEIS), including the HEIS Proximal Daily Activity Limitations (PDAL) and HEIS Embarrassment (Emb) subsets, were compared.
Results
Across the two trials, 639 patients were randomised to delgocitinib cream and 321 to cream vehicle. Delgocitinib cream resulted in significantly greater improvement in EQ‐5D, DLQI, HEIS, HEIS PDAL, and HEIS Emb compared with cream vehicle at week 16 (all p < 0.001). More patients achieved clinically meaningful improvement from baseline in patient‐reported outcomes at week 16 (all p < 0.001), and the mean time spent in an improved HRQoL state increased with delgocitinib cream.
Conclusions
Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. Clinical Trial ID DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Allergy Centre, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
- Division of Dermatology, Department of Medicine, Western University, London, Ontario, Canada.
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- LEO Pharma A/S, Ballerup, Denmark.
- Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Eydna Didriksen Apol, Marie Louise Schuttelaar
Förderung
- LEO Pharma
Zitieren
APA
Bauer, A., Guenther, L., Woolf, R., Didriksen Apol, E., Maslin, D., Nyholm, N., Thoning, H., & Schuttelaar, M. L. (2026). Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema. Contact Dermatitis, 95(1), 91-99. https://doi.org/10.1111/cod.70114
Vancouver
Bauer A, Guenther L, Woolf R, Didriksen Apol E, Maslin D, Nyholm N, et al. Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema. Contact Dermatitis. 2026;95(1):91-99. doi:10.1111/cod.70114
BibTeX
@article{Bauer2026,
author = {Bauer, Andrea and Guenther, Lyn and Woolf, Richard and Didriksen Apol, Eydna and Maslin, Douglas and Nyholm, Nanna and Thoning, Henrik and Schuttelaar, Marie Louise},
title = {Effect of Delgocitinib Cream on Health‐Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema},
journal = {Contact Dermatitis},
year = {2026},
volume = {95},
number = {1},
pages = {91--99},
doi = {10.1111/cod.70114}
}
EUVIMED